Schistosomiasis, also known as snail fever or bilharzia, is a disease caused by parasitic flatworms called schistosomes. The disease is classified into two forms that include intestinal and urogenital. The can be acute or chronic in nature. The symptoms of intestinal schistosomiasis include abdominal pain, diarrhea, liver and spleen enlargement, fibrosis of the bladder, and progressive damage of kidney. Other chronic symptoms include blood in stool and urine, genital lesions, nodules in vulva, seizures, paralysis, seminal vesicle, and vaginal bleeding. The condition can lead to urogenital schistosomiasis -related complication such as bladder cancer and long term irreversible consequences such as infertility.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/889
According to the World Health Organization’s (WHO) report in 2017, urogenital schistosomiasis is a high risk factor for the transmission of HIV infection in women and mediums include, agriculture, domestic, and occupational activities. Preventive chemotherapy for schistosomiasis includes praziquantel, metrifonate, and oxamniquine.
Parasitic species responsible for schistosomiasis and its geographical distribution by WHO:
| Species | Geographical Distribution | |
| Intestinal schistosomiasis | Schistosoma mansoni | Africa, the Middle East, the Caribbean, Brazil, Venezuela and Suriname |
| Schistosoma japonicum | China, Indonesia, and Philippines | |
| Schistosoma mekongi | Several districts of Cambodia and the Lao People’s Democratic Republic | |
| Schistosoma guineensis and related S. intercalatum | Rain forest areas of central Africa | |
| Urogenital Schistosomiasis | Schistosoma haematobium | Africa, the Middle East, Corsica (France) |
Global Schistosomiasis Treatment Market Taxonomy
On the basis of organ, the global schistosomiasis treatment market is segmented into:
- Intestinal
- Urogenital
On the basis of species, the global schistosomiasis treatment market is segmented into:
- Schistosoma mansoni
- Schistosoma japonicum
- Schistosoma mekongi
- Schistosoma guineensis
- Schistosoma haematobium
On the basis of drug type, the global schistosomiasis treatment market is segmented into:
- Praziquantel
- Metrifonate
- Biltricide
- Oxamniquine
- Others
On the basis of region, the global schistosomiasis treatment market is segmented into:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Purchase This Premium Report Here To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/889
Global Schistosomiasis Treatment Market: Drivers
Increasing prevalence of schistosomiasis is expected to aid in growth of the ggloba schistosomiasis treatment market over the forecast period. For instance, according to the World Health Organization (WHO), around 218 million people required preventive treatments for schistosomiasis in 2015 and more than 66.5 million people were reported as treated for schistosomiasis in the same year. Moreover, according to the same source, 78 countries reported transmission of schistosomiasis.
Increasing demand for preventive chemotherapy against schistosomiasis is also expected to aid in growth of the market. For instance, according to the World Health Organization (WHO), in 2017, around 92% people require preventive chemotherapy for schistosomiasis in Africa and around 75% of school aged children are at risk of morbidity from schistosomiasis and soil-transmitted helminthiasis. According to the same source, 207.7 million people worldwide required preventive chemotherapy in 2016, of which around 111.8 million were school-aged children. Moreover, lack of hygienic environment and safe drinking water in emerging economies is expected to propel the growth of the global schistosomiasis market.
Global Schistosomiasis Treatment Market: Restraints
However, lack of proper medication and vaccination is expected to hamper growth of the market.
Global Schistosomiasis Treatment Market: Opportunities
Increasing R&D of vaccines for the treatment of schistosomiasis is expected to offer lucrative growth opportunities for players in the global schistosomiasis treatment market. For instance, in 2015, Dr. Afzal Siddiqui, a professor at the Tech Health Sciences Center, received a patent for a vaccine for the treatment of schistosomiasis after the vaccine demonstrated positive endpoints in pre-clinical trials. In 2017, researchers at the University of Nottingham discovered the infiltrin protein on a parasitic egg, which may cause schistosomiasis. Similarly, in the same year, the College of Science at Oregon State University reportedly identified a new protein in Biomphalaria glabrata snail, known as Grctm6. Such developments may facilitate introduction of effective vaccines against the disease.
Moreover, increasing initiatives by public and private organizations for treatment and management of schistosomiasis is also expected to aid in growth of the market. For instance, in May 2017, Global Schistosomiasis Alliance organized Neglected Tropical Diseases (NTDs) program hosted by World Health Organizations (WHO). Moreover, the program was supported by the Chinese Centers for Disease Control and Prevention (CDC), Research for Control and Elimination (SCORE), Swiss Tropical and Public Health Institute, The Federal Ministry of Health Ethiopia (FMHE), and The Ministry of Health (MoH).
Global Schistosomiasis Treatment Market: Competitive Landscape
Major players operating in the global schistosomiasis treatment market include, Chemos GmbH & Co. KG, Shin Poong Pharma.Co. Ltd., Meher Distributors Pvt. Ltd., Merck & Co., Salvensis, Bayer AG, LondonPharma Ltd, Merck & Co., Inc., 3S Corporation Kancera AB, aj Pharmaceuticals Ltd., Avanscure Lifesciences Pvt. Ltd, CBC Pharma., VHB Life Science Inc., Samarth Pharma Pvt. Ltd., Taj Pharmaceuticals Ltd., and Egyptian International Pharmaceuticals Industries Co SAE (EIPICO).
Get Sample Report with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-sample/889
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837